Key takeaways
- Novo's experimental drug CagriSema achieved 12.4% weight loss in a late-stage diabetes trial, beating Eli Lilly's tirzepatide (5 mg).
What happened
Novo announced that its experimental dual-action drug CagriSema outperformed Eli Lilly’s market-leading tirzepatide in a late-stage clinical trial for patients with type 2 diabetes. According to Reuters, the REIMAGINE 5 trial demonstrated that a 1.0 mg dose of CagriSema delivered an average weight loss of 12.4%, compared to 9.1% for patients taking a 5 mg dose of tirzepatide. The drugmaker also revealed plans to launch the blockbuster treatment in early 2025, pending an upcoming regulatory decision.
Why it matters
This trial represents a major escalation in the battle for the next generation of medical weight loss. Right now, US consumers buying brand-name GLP-1 medications are largely choosing between Novo’s Wegovy and Eli Lilly’s Zepbound. However, patents on Wegovy are set to expire after 2030, forcing Novo to develop a potent successor.
For the millions of Americans who pay cash or use online telehealth providers to access weight-loss treatments, the arrival of CagriSema could fundamentally reshape the market. This dual-action injection combines semaglutide (the active ingredient in Wegovy) with cagrilintide (an amylin analog) to target two different hunger pathways at once. If approved, it will give cash-paying US buyers a highly potent alternative to existing brand-name drugs and potentially pressure telehealth providers to adjust their monthly bundle pricing.
What the data says
The data from Novo's latest trials outlines a clear picture of CagriSema's clinical profile:
- REIMAGINE 5 Trial: A 1.0 mg dose of CagriSema achieved an average weight loss of 12.4% in adults with type 2 diabetes.
- Tirzepatide Comparison: In the head-to-head comparison, Eli Lilly’s tirzepatide at a 5 mg dose achieved a lower average weight loss of 9.1%.
- Blood Sugar Control: The trial demonstrated that CagriSema achieved "non-inferior" blood sugar reduction when compared directly to tirzepatide.
- Obesity Trial Results: In a separate late-stage study evaluating adults with obesity (without diabetes), a 1.0 mg dose of CagriSema led to a 21% weight loss compared to a placebo.
Despite the strong performance, market analysts noted some nuance. A BMO analyst reported to Reuters that the low-dose trial victory, while encouraging, was less impactful because tirzepatide has already proven superior to higher doses of CagriSema in previous obesity-specific trials.
How it compares
To understand how CagriSema compares to what is currently available on the market, it helps to look at the mechanisms and the financial landscape for US buyers.
Currently, Wegovy relies solely on semaglutide to mimic the GLP-1 hormone. Zepbound (tirzepatide) mimics both GLP-1 and GIP, which has historically given Eli Lilly a clinical edge in weight-loss efficacy. CagriSema introduces a third mechanism by combining semaglutide with cagrilintide, which mimics the pancreatic hormone amylin to increase feelings of fullness.
For cash-paying consumers, existing brand-name GLP-1 medications are famously expensive. Retail prices for Zepbound and Wegovy hover between $1,000 and $1,350 per month without insurance. Many patients turn to online platforms to find cheapest telehealth glp-1 options or explore compounded vs brand name semaglutide to manage monthly costs. If CagriSema launches early next year, Novo will likely price it as a premium product, meaning it will initially sit at the top of the cash-price spectrum. However, its superior efficacy could force Eli Lilly to reconsider its pricing strategy for Zepbound, potentially trickling down to lower out-of-pocket costs across the board.
How this fits the bigger picture
This clinical milestone is a direct response to Novo’s need to secure its market share before its blockbusters lose patent protection. We previously reported on how the company is shifting its commercial focus in our analysis of how Novo outlines direct-to-consumer strategy, which highlights the drugmaker's plans to launch five new blockbuster drugs by 2030 to bypass traditional insurance hurdles and capture cash-paying buyers directly. CagriSema is the crown jewel of this upcoming portfolio.
Furthermore, Novo's corporate restructuring reflects its preparation for this high-stakes next-generation rollout. As we analyzed in our coverage of how Novo Nordisk rebrands to ‘Novo’, the corporate identity shift was designed to streamline the brand as it battles Eli Lilly for dominance. Beating Lilly's tirzepatide in a late-stage diabetes trial gives Novo a powerful marketing tool to rebuild momentum after its previous clinical setback, where CagriSema fell short against high-dose Zepbound in an earlier head-to-head obesity trial.
For patients navigating the current US market, visiting a providers page or using an online compare tool remains the most practical way to find affordable options today. However, the successful trial of CagriSema suggests that the clinical options available through these platforms will look vastly different—and much more powerful—by the end of the decade.
What happens next
The path forward for CagriSema is moving rapidly. The US Food and Drug Administration (FDA) is expected to hand down a regulatory decision on Novo’s application for CagriSema for weight management in the fourth quarter.
If the FDA grants approval, Novo plans to proceed with a commercial rollout. During its capital markets day, the drugmaker outlined a multi-year launch strategy targeting an initial commercial release of the CagriSema combination in early next year. Healthcare providers and cash-paying consumers should expect more details on US pricing, distribution, and telehealth availability once the FDA issues its final ruling.
CompareRx provides factual educational content and news analysis regarding medical weight-loss options. We do not provide medical advice. Consult a licensed healthcare provider to determine the appropriate treatment plan for your individual health needs.